<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81929</article-id><article-id pub-id-type="doi">10.7554/eLife.81929</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-289653"><name><surname>Lauer</surname><given-names>Richard C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-289654"><name><surname>Barry</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-259466"><name><surname>Smith</surname><given-names>Tracey L</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219501"><name><surname>Thomas</surname><given-names>Andrew Maltez</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5789-3354</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289655"><name><surname>Wu</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289656"><name><surname>Du</surname><given-names>Ruofei</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289657"><name><surname>Lee</surname><given-names>Ji-Hyun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6420-5150</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289658"><name><surname>Rao</surname><given-names>Arpit</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289659"><name><surname>Dobroff</surname><given-names>Andrey S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-289660"><name><surname>Arap</surname><given-names>Marco A</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216767"><name><surname>Nunes</surname><given-names>Diana N</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-31917"><name><surname>Silva</surname><given-names>Israel T</given-names></name><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216768"><name><surname>Dias-Neto</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-289661"><name><surname>Chen</surname><given-names>Isan</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-289662"><name><surname>McCance</surname><given-names>Dennis J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-261953"><name><surname>Cavenee</surname><given-names>Webster K</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-216782"><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><email>renata.pasqualini@rutgers.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-216139"><name><surname>Arap</surname><given-names>Wadih</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8686-4584</contrib-id><email>wadih.arap@rutgers.edu</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf6"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05fs6jp91</institution-id><institution>University of New Mexico Comprehensive Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Albuquerque, New Mexico</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05fs6jp91</institution-id><institution>Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Albuquerque, New Mexico</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r0ha626</institution-id><institution>Department of Pathology, University of Utah</institution></institution-wrap><addr-line><named-content content-type="city">Salt Lake City, Utah</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vt9qd57</institution-id><institution>Rutgers Cancer Institute of New Jersey</institution></institution-wrap><addr-line><named-content content-type="city">Newark, New Jersey</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vt9qd57</institution-id><institution>Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Newark, New Jersey</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Department of Biochemistry, Institute of Chemistry, University of São Paulo</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05fs6jp91</institution-id><institution>Department of Pathology, University of New Mexico</institution></institution-wrap><addr-line><named-content content-type="city">Albuquerque, New Mexico</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00xcryt71</institution-id><institution>Department of Biostatistics, University of Arkansas for Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Little Rock, Arkansas</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y3ad647</institution-id><institution>Department of Biostatistics, University of Florida</institution></institution-wrap><addr-line><named-content content-type="city">Gainesville, Florida</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02y3ad647</institution-id><institution>Division of Quantitative Sciences, University of Florida Health Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Gainesville, Florida</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston, Texas</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Division of Molecular Medicine, Department of Medicine</institution><addr-line><named-content content-type="city">Albuquerque</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036rp1748</institution-id><institution>Division of Urology, University of São Paulo Medical School</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r5mk904</institution-id><institution>Syrian-Lebanese Hospital</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03025ga79</institution-id><institution>Laboratory of Medical Genomics, A.C. Camargo Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03025ga79</institution-id><institution>Laboratory of Bioinformatics and Computational Biology, A.C. Camargo Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/051zy3f83</institution-id><institution>MBrace Therapeutics</institution></institution-wrap><addr-line><named-content content-type="city">San Diego, California</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0168r3w48</institution-id><institution>Ludwig Institute for Cancer Research, University of California, San Diego</institution></institution-wrap><addr-line><named-content content-type="city">La Jolla, California</named-content></addr-line><country>United States</country></aff><aff id="aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05vt9qd57</institution-id><institution>Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Newark, New Jersey</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v408z34</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v408z34</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>16</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81929</elocation-id><history><date date-type="received" iso-8601-date="2022-07-16"><day>16</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-13"><day>13</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-10-30"><day>30</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.25.22281522"/></event></pub-history><permissions><copyright-statement>© 2023, Lauer, Barry et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Lauer, Barry et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81929-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81929-figures-v3.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>We have previously shown that the long non-coding (lnc)RNA <italic>prostate cancer associated 3</italic> (<italic>PCA3</italic>; formerly <italic>prostate cancer antigen 3</italic>) functions as a trans-dominant negative oncogene by targeting the previously unrecognized prostate cancer suppressor gene <italic>PRUNE2</italic> (a homolog of the <italic>Drosophila prune</italic> gene), thereby forming a functional unit within a unique allelic locus in human cells. Here, we investigated the <italic>PCA3</italic>/<italic>PRUNE2</italic> regulatory axis from early (tumorigenic) to late (biochemical recurrence) genetic events during human prostate cancer progression.</p></sec><sec id="abs2"><title>Methods:</title><p>The reciprocal <italic>PCA3</italic> and <italic>PRUNE2</italic> gene expression relationship in paired prostate cancer and adjacent normal prostate was analyzed in two independent retrospective cohorts of clinically annotated cases post-radical prostatectomy: a single-institutional discovery cohort (n=107) and a multi-institutional validation cohort (n=497). We compared the tumor gene expression of <italic>PCA3</italic> and <italic>PRUNE2</italic> to their corresponding expression in the normal prostate. We also serially examined clinical/pathological variables including time to disease recurrence.</p></sec><sec id="abs3"><title>Results:</title><p>We consistently observed increased expression of <italic>PCA3</italic> and decreased expression of <italic>PRUNE2</italic> in prostate cancer compared with the adjacent normal prostate across all tumor grades and stages. However, there was no association between the relative gene expression levels of <italic>PCA3</italic> or <italic>PRUNE2</italic> and time to disease recurrence, independent of tumor grades and stages.</p></sec><sec id="abs4"><title>Conclusions:</title><p>We concluded that upregulation of the lncRNA <italic>PCA3</italic> and targeted downregulation of the protein-coding <italic>PRUNE2</italic> gene in prostate cancer could be early (rather than late) molecular events in the progression of human prostate tumorigenesis but are not associated with biochemical recurrence. Further studies of PCA3/PRUNE2 dysregulation are warranted.</p></sec><sec id="abs5"><title>Funding:</title><p>We received support from the Human Tissue Repository and Tissue Analysis Shared Resource from the Department of Pathology of the University of New Mexico School of Medicine and a pilot award from the University of New Mexico Comprehensive Cancer Center. RP and WA were supported by awards from the Levy-Longenbaugh Donor-Advised Fund and the Prostate Cancer Foundation. EDN reports research fellowship support from the Brazilian National Council for Scientific and Technological Development (CNPq), Brazil, and the Associação Beneficente Alzira Denise Hertzog Silva (ABADHS), Brazil. This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of New Mexico Comprehensive Cancer Center (CA118100) and the Rutgers Cancer Institute of New Jersey (CA072720).</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>PCA3</kwd><kwd>PRUNE2</kwd><kwd>prostate cancer</kwd><kwd>long non-coding RNA</kwd><kwd>oncogene</kwd><kwd>tumor suppressor gene</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA118100</award-id><principal-award-recipient><name><surname>Lauer</surname><given-names>Richard C</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA072720</award-id><principal-award-recipient><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Levy-Longenbaugh Donor-Advised Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000892</institution-id><institution>Prostate Cancer Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100014555</institution-id><institution>Foundation for Scientific and Technological Development in Health</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dias-Neto</surname><given-names>Emmanuel</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Associação Beneficente Alzira Denise Hertzog Silva</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Dias-Neto</surname><given-names>Emmanuel</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007179</institution-id><institution>University of New Mexico</institution></institution-wrap></funding-source><award-id>Comprehensive Cancer Center Pilot Award</award-id><principal-award-recipient><name><surname>Lauer</surname><given-names>Richard C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value><italic>PRUNE2</italic>/<italic>PCA3</italic> axis dysregulation is an early, rather than late, event in prostate cancer tumorigenesis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Prostate cancer is the most common cancer and the second most common cause of cancer death in men (<xref ref-type="bibr" rid="bib27">Siegel et al., 2021</xref>), and there continues to be a pressing need for new diagnostic and therapeutic approaches for this disease, as well as better prognostic biomarkers to guide treatment. Long non-coding RNA (lncRNA) species are increasingly recognized as having regulatory functions in tumorigenesis, and nucleic acid-based therapeutics are being developed as a promising means of targeting pathogenic lncRNAs (<xref ref-type="bibr" rid="bib3">Arun et al., 2018</xref>). Several lncRNAs have recently been found to associate with prostate cancer, and the best known of these, <italic>prostate cancer associated 3</italic> (<italic>PCA3</italic>; formerly <italic>prostate cancer antigen 3</italic>) has been used clinically for many years as the most specific diagnostic biomarker for prostate cancer (<xref ref-type="bibr" rid="bib5">Bussemakers et al., 1999</xref>; <xref ref-type="bibr" rid="bib9">de Kok et al., 2002</xref>); however, its prognostic significance remains uncertain. Strikingly, <italic>PCA3</italic> emerged first only in mammals, with further evolution in primates (<xref ref-type="bibr" rid="bib8">Clarke et al., 2009</xref>), and, given aspects of the sequence and genomic organization, we have hypothesized that it might have been introduced into the genome by an ancient oncogenic virus (<xref ref-type="bibr" rid="bib29">Teixeira et al., 2017</xref>). In humans, <italic>PCA3</italic> has an unusual genomic organization, being present in an antisense direction within an intron of the protein-coding gene <italic>PRUNE2</italic>. Somewhat surprisingly for a molecule that is well established as a Food and Drug Administration (FDA)- and European Medical Agency (EMA)-approved biomarker, relatively little was known about the biological function of <italic>PCA3</italic> until recently. <xref ref-type="bibr" rid="bib11">Ferreira et al., 2012</xref>, showed that <italic>PCA3</italic> is androgen-regulated and that it promotes prostate cancer cell survival. Subsequently, we have established that <italic>PCA3</italic> downregulates the expression of <italic>PRUNE2</italic> in a rather unusual way: at the RNA level by RNA editing mediated via adenosine deaminase RNA-specific family members (<xref ref-type="bibr" rid="bib26">Salameh et al., 2015</xref>). We have shown that expressing ectopic <italic>PCA3</italic> or, alternatively, silencing <italic>PRUNE2</italic> induced cell transformation and cell proliferation in vitro, increased adhesion and migration of prostate cancer cells, and yielded larger tumors in xenograft tumor models. The opposite biological effects were seen with <italic>PCA3</italic> silencing or ectopic <italic>PRUNE2</italic> expression (<xref ref-type="bibr" rid="bib26">Salameh et al., 2015</xref>). Preliminary studies of human prostate cancer samples compared to normal prostate showed increased <italic>PCA3</italic> expression, decreased <italic>PRUNE2</italic> expression, and evidence for RNA editing of these genes. Based on these experimental findings, we proposed that there is a functional molecular axis in human prostate cancer in which <italic>PCA3</italic> acts as a transdominant-negative oncogene to downregulate a previously unrecognized tumor suppressor gene, <italic>PRUNE2</italic> (<xref ref-type="bibr" rid="bib26">Salameh et al., 2015</xref>).</p><p>Here, we propose that this molecular interplay may serve as a translational target for diagnostic and/or therapeutic intervention in human prostate cancer. First, we present additional correlative evidence from two retrospective post-surgical primary prostate cancer cohorts in support of our experimental model of <italic>PCA3</italic> as a dominant-negative oncogene and <italic>PRUNE2</italic> as a tumor suppressor gene and for their co-regulation in human prostate cancer. Moreover, we examine the dysregulation of the <italic>PCA3</italic>/<italic>PRUNE2</italic> regulatory axis across tumors of different grades (patterns), stages, and groups (<xref ref-type="bibr" rid="bib13">Gordetsky and Epstein, 2016</xref>; <xref ref-type="bibr" rid="bib32">van Leenders et al., 2020</xref>). Finally, we assess whether tumor expression levels of <italic>PCA3</italic> and/or <italic>PRUNE2</italic> are prognostic of biochemical disease recurrence after surgery.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Discovery patient cohort</title><p>Based on a power analysis using gene expression data from our prior work (<xref ref-type="bibr" rid="bib26">Salameh et al., 2015</xref>), for the UNMCCC single-institutional discovery cohort, we searched the archives of the Department of Pathology at the UNM School of Medicine for at least 100 consecutive patients (final cohort size: n=107) who had a radical prostatectomy as the primary treatment for organ-confined prostate cancer between the years 2001 and 2013 and who had the following clinical and pathological attributes: final post-prostatectomy Gleason Score 7 (either Gleason Grade Group 2 (3+4) or Gleason Grade Group 3 (4+3)), pathological stage pT2 or pT3a, negative surgical margins, negative for seminal vesicle invasion, no evidence of local or distant metastasis, and no prior treatment for prostate cancer. The following additional data were retrospectively abstracted from the individual medical records: age at surgery, race, presence of recurrence, type of recurrence (i.e., biochemical, local, metastatic), and disease-free survival time. Biochemical disease recurrence was defined as a detectable serum prostate-specific antigen concentration of at least 0.2 ng/ml post-operatively. Lost to follow up was defined as not having been followed up at the UNMCCC after their urological surgery. All included cases had an independent pathological re-review by a Board-certified pathologist with expertise in urological pathology (MB), with confirmation of diagnosis, Gleason-based analysis (grading, scoring, and grouping), standard TNM staging, and margin status post-resection. A small number of identified cases (&lt;5%) had to be excluded due to the very limited amount of tumor present.</p></sec><sec id="s2-2"><title>Microdissection of tumor and normal prostate (nonneoplastic prostatic glandular tissue) for the discovery cohort</title><p>To obtain tumor for RNA analysis, a representative carcinoma-containing formalin-fixed paraffin embedded (FFPE) block was chosen from each case. Contiguous foci of tumor were marked on the glass slide such that the density of tumor cells was at least 75%. The boundary of the corresponding areas on the tumor block was scored with a blade tip, effectively allowing microdissection of tumor in the process of microtome sectioning. Multiple 10 µm sections were cut, depending on the area of the tumor focus/foci. In 24 (22.4%) of the cases, we also microdissected areas of nonneoplastic prostatic glandular tissue away from tumor in a similar manner, again also aiming for at least 75% epithelial density.</p></sec><sec id="s2-3"><title>Measurement of PRUNE2 and PCA3 gene expression in the discovery cohort by quantitative RT-PCR</title><p>Briefly, gene expression for <italic>PCA3</italic> and <italic>PRUNE2</italic> were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) by using TaqMan gene expression assays (Thermo Fisher Scientific) with amplicon detection via a LightCycler 96 (Roche Diagnostics). Gene expression was quantified by the relative logarithmic RT-PCR threshold cycles (∆Ct) between the target genes and housekeeping control genes (<xref ref-type="bibr" rid="bib19">Livak and Schmittgen, 2001</xref>). Specifically, total RNA was extracted from the microdissected FFPE sections using the PureLink FFPE Total RNA Isolation Kit (Thermo Fisher Scientific, Cat. No. K1560-02). RNA was quantified on a NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific), and the average A260/A280 ratio was 1.94 (range 1.88–2.07), indicating optimal quality of the RNA extracted for gene expression assays. RNA was then further quantified with the Qubit RNA HS Assay Kit (Thermo Fisher Scientific, Cat. No. Q32852) on a Qubit 2.0 (Thermo Fisher Scientific) for accurate RNA concentration. RNA integrity was evaluated with the Agilent RNA 6000 Nano kit (Agilent Technologies, Cat. No. 5067-1511) on an Agilent 2100 Bioanalyzer (Agilent Technologies). To remove genomic DNA contamination, RNA samples were treated with 2 U of DNase I (Thermo Fisher Scientific, Cat. No. 18068-015) per 2 µg of total RNA. All procedures were performed according to the manufacturer’s standard protocols.</p><p>Reverse transcription was performed in triplicate in order to create enough cDNA for the entire project. Five-hundred ng RNA in each of three tubes was reverse transcribed with the High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific, Cat. No. 4387406) in a final volume of 20 µl, according to the manufacturer’s instructions. Reverse transcription was carried out in a Gene Amp PCR System 9700 (Applied Biosystems) at 37°C for 60 min and terminated by 95°C for 5 min. Then, three aliquots were combined for the following experiments.</p><p>For the Thermo Fisher Scientific TaqMan gene expression assay experiments, three (Hs00322421_m1, Hs00999960_m1, and Hs01060890_m1) and two (Hs01371939_g1 and Hs03462121_m1) assays were chosen for target genes <italic>PRUNE2</italic> and <italic>PCA3,</italic> respectively (designated PR1, PR2, and PR3, and PC1 and PC2). Three endogenous controls GAPDH (Hs02758991_g1), HPRT1 (Hs02800695_m1), and UBC (Hs01871556_s1) were selected (designated C1, C2, and C3) (<xref ref-type="bibr" rid="bib31">Vandesompele et al., 2002</xref>). Each <italic>PRUNE2</italic> assay and <italic>PCA3</italic> assay was labeled with FAM and paired with a VIC-labeled endogenous control in a duplex reaction, with separate reactions to include all of the three endogenous controls. Therefore, a total of fifteen duplex gene expression mixes, nine for <italic>PRUNE2</italic> and six for <italic>PCA3</italic>, was required for all specimens (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> [tumor] and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> [normal]).</p><p>Each duplex gene expression assay was then performed in triplicate for all specimens following the manufacturer’s standard protocols, for a total of 45 expression measures for each case. qRT-PCR was performed with the TaqMan Gene Expression Master Mix (Thermo Fisher Scientific, Cat. No. 4369514) using 1 µl of each TaqMan target gene assay (20× FAM) and endogenous controls assay (20× VIC), 1 µl of cDNA template (equivalent to 25 ng RNA input), and 7 µl of RNase-free water for a 20 μl final reaction mixture. A non-template control was included in every master mix in every 96-format tray. In addition, in order to evaluate inter-plate variation, we also included one RNA sample, in triplicate, in all the 96-format trays. Analysis of these controls indicated that there were no significant batch effects (data not shown). The qRT-PCR product detection was achieved on a LightCycler 96 (Roche Diagnostics). The cycle program was: at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and at 60°C for 1 min. Quantification of target and control genes (Cq) in each sample was performed by LightCycler 96 SW 1.1 (Roche Diagnostics).</p></sec><sec id="s2-4"><title>Validation patient cohort</title><p>For The Cancer Genome Atlas (TCGA) patient validation cohort (n=497 patients), we first downloaded clinical data along with the expression of the lncRNA <italic>PCA3</italic> and the <italic>PRUNE2</italic> gene (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov">http://cancergenome.nih.gov</ext-link>) with the UCSC Xena browser (<xref ref-type="bibr" rid="bib6">Cancer Genome Atlas Research Network, 2015</xref>; <xref ref-type="bibr" rid="bib30">University of North Carolina TCGA Genome Characterization Center, 2017</xref>), together with paired nonneoplastic samples in 52 of the cases (10.5%). The following clinical and pathological characteristics were included in the study: age at diagnosis, vital status, tumor Gleason-based analysis (grading, scoring, grouping), pathological stage, status of biochemical recurrence, and time to recurrence. Gene expression was calculated with log<sub>2</sub>RNA-Seq by Expectation-Maximization (RSEM) (<xref ref-type="bibr" rid="bib18">Li and Dewey, 2011</xref>; <xref ref-type="bibr" rid="bib12">Goldman et al., 2020</xref>). By using the available dataset, we evaluated <italic>PCA3</italic> and <italic>PRUNE2</italic> gene expression values in terms of tumor versus nonneoplastic prostate, biochemical recurrence, pathological T stage, Gleason analysis (grade, score, and group), and age at pathology-proven diagnosis. Because the regulation of <italic>PRUNE2</italic> by <italic>PCA3</italic> occurs at the RNA level by the formation of an RNA hetero-duplex, we also evaluated the ratio of the expression of the two genes in terms of the clinical and pathological variables for each patient of the cohort.</p></sec><sec id="s2-5"><title>Statistics</title><p>Demographic and clinical variables were summarized with descriptive statistics. For the discovery cohort, the mean and median of gene expressions across multiple control genes and assays were summarized, and these were used as measures for gene expression of <italic>PRUNE2</italic> and <italic>PCA3</italic> relative to endogenous housekeeping controls for each case. More detailed methods are described in Appendix 1.</p><p>Testing for differences of <italic>PCA3</italic> and <italic>PRUNE2</italic> expression between paired tumor and nonneoplastic prostate expression was by the Wilcoxon signed rank test. The Kruskal-Wallis test was used when comparing three or more groups. Assessment for significant differences of gene expression by recurrence status was by Wilcoxon rank sum test. The Kaplan-Meier product limit method with log-rank test was used to explore the relationship between gene expression levels or the ratio and the time to recurrence. Multivariable Cox proportional hazard modeling was used to fit for the association between time to recurrence and expression levels of <italic>PRUNE2</italic> or <italic>PCA3</italic> or their ratio, while controlling for multiple clinical covariates. All statistical analyses were carried out by using the SAS (9.4) or R software package (R 3.4.5), unless otherwise indicated (R and SAS codes are available in the <xref ref-type="supplementary-material" rid="scode1">Source code 1</xref>).</p><sec id="s2-5-1"><title>Study approval</title><p>For the discovery cohort, there was University of New Mexico Health Sciences Institutional Review Board (IRB) approval (HRRC15-138), and the study was carried out in accordance with the United States Common Rule.</p></sec></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Discovery single-institutional cohort</title><p>In the initial single-institutional discovery cohort from the University of New Mexico Comprehensive Cancer Center (UNMCCC), patients with intermediate-risk (Gleason Score 7; corresponding to Gleason Groups 2 and 3) organ-confined prostate cancer (n=107) met the criteria for inclusion in this study (<xref ref-type="table" rid="table1">Table 1</xref>). Briefly, the mean age of the cohort was 63 years (ranging from 45 to 84 years); most patients (85%) were non-Hispanic white, but Hispanic (7.5%), American Indian/Native American (2.8%), and African American (2.8%) men were also represented. All patients had final Gleason Score 7 adenocarcinoma after radical prostatectomy, with 86.9% being 3+4 = 7 (Gleason Grade Group 2) and 13.1% being 4+3 = 7 (Gleason Grade Group 3). The pathological stage distribution was as follows: 74.8% were pT2 and 25.2% were pT3a. Nineteen of the patients (17.8%) had biochemical recurrence discovered during follow-up, including one with documented local recurrence and one with documented metastases. Five patients (4.7%) were lost to follow up.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Discovery cohort: clinicopathological features of the 107patients in this study who had radical prostatectomy at UNM for localized prostatic adenocarcinoma (further details in <xref ref-type="supplementary-material" rid="table1sdata1">Table 1—source data 1</xref>).</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Discovery cohort.</title><p>Clinicopathological features of the 107 patients in this study who had radical prostatectomy at UNM for localized prostatic adenocarcinoma.</p></caption><media mimetype="application" mime-subtype="octet-stream" xlink:href="elife-81929-table1-data1-v3.csv"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variable</th><th align="left" valign="bottom">Number</th><th align="left" valign="bottom">% or Mean (STD; range)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Age (years)</td><td align="left" valign="bottom">107</td><td align="left" valign="bottom">62.8 (8.4; 45–84)</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="3">Race</td></tr><tr><td align="left" valign="bottom"> Non-Hispanic White</td><td align="left" valign="bottom">91</td><td align="left" valign="bottom">85</td></tr><tr><td align="left" valign="bottom"> Hispanic</td><td align="left" valign="bottom">8</td><td align="left" valign="bottom">7.5</td></tr><tr><td align="left" valign="bottom"> American Indian</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">2.8</td></tr><tr><td align="left" valign="bottom"> African American</td><td align="left" valign="bottom">3</td><td align="left" valign="bottom">2.8</td></tr><tr><td align="left" valign="bottom"> Other</td><td align="left" valign="bottom">2</td><td align="left" valign="bottom">1.9</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="3">Post-prostatectomy Gleason Grade (Grade Group)</td></tr><tr><td align="left" valign="bottom"> 3+4 = 7 (Grade Group 2)</td><td align="left" valign="bottom">93</td><td align="left" valign="bottom">86.9</td></tr><tr><td align="left" valign="bottom"> 4+3 = 7 (Grade Group 3)</td><td align="left" valign="bottom">14</td><td align="left" valign="bottom">13.1</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="3">Pathological stage</td></tr><tr><td align="left" valign="bottom"> pT2</td><td align="left" valign="bottom">80</td><td align="left" valign="bottom">74.8</td></tr><tr><td align="left" valign="bottom"> pT3a</td><td align="left" valign="bottom">27</td><td align="left" valign="bottom">25.2</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="3">Biochemical recurrence status</td></tr><tr><td align="left" valign="bottom"> No</td><td align="left" valign="bottom">83</td><td align="left" valign="bottom">77.6</td></tr><tr><td align="left" valign="bottom"> Yes</td><td align="left" valign="bottom">19</td><td align="left" valign="bottom">17.8</td></tr><tr><td align="left" valign="bottom"> LTF</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">4.7</td></tr></tbody></table><table-wrap-foot><fn><p>STD, standard deviation; LTF, lost to follow up.</p></fn></table-wrap-foot></table-wrap><p>RNA extraction and qRT-PCR were successful in all microdissected tumor samples (n=107). In 24 of these cases (22.4%), we extracted RNA from benign prostatic glandular tissue away from tumor (hereafter termed ‘normal prostate’: qRT-PCR was successful in all cases for <italic>PRUNE2</italic> [n=24, 100%] and in most cases for <italic>PCA3</italic> [n=21, 87.5%]). Comparing <italic>PRUNE2</italic> and <italic>PCA3</italic> expression in prostatic adenocarcinoma with expression in normal prostate (all relative to endogenous housekeeping controls), we found consistent trends for both genes in multiple assays, with lower expression of <italic>PRUNE2</italic> in tumor as compared with normal prostate and higher expression of <italic>PCA3</italic> in tumor as compared with normal prostate (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). These results are summarized in <xref ref-type="fig" rid="fig1">Figure 1A</xref> and as follows. Relative to controls, <italic>PCA3</italic> expression was significantly higher in prostatic adenocarcinoma (mean: 2.46; standard deviation: 1.28) than normal prostate (–1.99; 2.63, [p-value &lt;0.001]). Relative to controls, <italic>PRUNE2</italic> expression was significantly lower in tumor (mean: –1.48; standard deviation: 0.92) than normal prostate (–0.78; 0.4, [p-value &lt;0.001]).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Analyses of discovery prostate cancer cohort.</title><p>(<bold>A</bold>) <italic>PRUNE2</italic> and <italic>PCA3</italic> expression in tumor (n=107) (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>) and nonneoplastic (n=24 for <italic>PRUNE2</italic>, n=21 for <italic>PCA3</italic>) (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>) prostatic samples. Calculated values available in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. (<bold>B</bold>) Tumor <italic>PCA3</italic> expression by biochemical recurrence status. <italic>PCA3</italic> expression in patients without versus with biochemical recurrence in the discovery cohort (n=102). No significant difference in median expression was seen in this cohort. Box plots of gene expression (normalized expression) in the discovery cohort. The horizontal line within each box represents the median value, while the box represents the interquartile range, and the whiskers extend out to 1.5 times the interquartile range. Outliers are represented by circles. p-Values are noted for the indicated comparisons.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Analyses of discovery prostate cancer cohort.</title><p>Raw values of <italic>PRUNE2</italic> and <italic>PCA3</italic> expression in tumor prostatic samples.</p></caption><media mimetype="application" mime-subtype="octet-stream" xlink:href="elife-81929-fig1-data1-v3.csv"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Analyses of discovery prostate cancer cohort.</title><p>Raw values of <italic>PRUNE2</italic> and <italic>PCA3</italic> expression in nonneoplastic prostatic samples.</p></caption><media mimetype="application" mime-subtype="octet-stream" xlink:href="elife-81929-fig1-data2-v3.csv"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Analyses of discovery prostate cancer cohort.</title><p>Calculated values of <italic>PRUNE2</italic> and <italic>PCA3</italic> expression in tumor and nonneoplastic prostatic samples.</p></caption><media mimetype="text" mime-subtype="plain" xlink:href="elife-81929-fig1-data3-v3.txt"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81929-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Discovery cohort – no significant difference in tumor <italic>PRUNE2</italic> expression by biochemical recurrence status.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81929-fig1-figsupp1-v3.tif"/></fig></fig-group><p>We next explored the association between biochemical recurrence and tumor expression levels of <italic>PRUNE2</italic>, <italic>PCA3,</italic> and the ratio of <italic>PRUNE2</italic> to <italic>PCA3</italic> expression by using several approaches. First, we compared the gene expression values and their ratio by recurrence status. In patients who recurred compared to those who did not, we found no significant difference in mean expression values of <italic>PRUNE2</italic> (−1.6 to –1.58; p-value = 0.68), <italic>PCA3</italic> (2.98 versus 2.43; p-value = 0.16), or their ratio (−1.61 to –1.21, p-value = 0.48). The different expression levels by recurrence were not significant (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Next, for <italic>PRUNE2</italic> expression, <italic>PCA3</italic> expression, and their ratio, we regrouped the cancer cases according to whether the values were greater than (deemed ‘high’) or less than/equal to (deemed ‘low’) their respective mean values. By using the Kaplan-Meier product limit methodology and the log-rank test, we found no significant associations between high or low levels and time to recurrence for <italic>PRUNE2</italic> expression (p-value = 0.24), <italic>PCA3</italic> expression (p-value = 0.22) (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="table" rid="table2 table3">Tables 2–3</xref>), or their ratio (p-value = 0.84). As a further assessment of association between gene expression and time to biochemical recurrence, we used Cox proportional hazards modeling and found no significant associations of time to biochemical recurrence with expression of <italic>PRUNE2</italic> (hazard ratio [HR]: 0.97; 95% confidence interval [CI]: 0.58–1.63, [p-value = 0.91]) or <italic>PCA3</italic> (HR: 1.21; 95% CI: 0.91–1.6, [p-value = 0.19]), or their ratio (HR: 0.99; 95% CI: 0.92–1.1, [p-value = 0.82]). By multivariable Cox modeling, we did not find that expression of <italic>PRUNE2</italic>, <italic>PCA3,</italic> or their ratio added any additional predictive information for recurrence to that provided by clinical or pathological variables, as presented in Appendix 1 and <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Kaplan-Meier curves illustrating time to event (biochemical recurrence) among patients post-prostatectomy from the discovery cohort, stratified by ‘high’ gene expression (greater than mean expression, red line) versus ‘low’ gene expression (less than or equal to mean expression, blue line), for (<bold>A</bold>) tumor <italic>PRUNE2</italic> expression, and (<bold>B</bold>) tumor <italic>PCA3</italic> expression.</title><p>There was no significant association of high versus low expression levels and time to recurrence by log-rank testing for either <italic>PRUNE2</italic> or <italic>PCA3</italic>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81929-fig2-v3.tif"/></fig><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Number of patients at risk over time (see <xref ref-type="fig" rid="fig2">Figure 2A</xref>).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="center" valign="bottom" colspan="4">Years post radical prostatectomy</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>PRUNE2</italic> expression</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">15</td></tr><tr><td align="left" valign="bottom">High</td><td align="char" char="." valign="bottom">51</td><td align="char" char="." valign="bottom">15</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Low</td><td align="char" char="." valign="bottom">56</td><td align="char" char="." valign="bottom">14</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">0</td></tr></tbody></table></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Number of patients at risk over time (see <xref ref-type="fig" rid="fig2">Figure 2B</xref>).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="center" valign="bottom" colspan="4">Years post radical prostatectomy</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>PCA3</italic> expression</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">10</td><td align="char" char="." valign="bottom">15</td></tr><tr><td align="left" valign="bottom">High</td><td align="char" char="." valign="bottom">59</td><td align="char" char="." valign="bottom">16</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">0</td></tr><tr><td align="left" valign="bottom">Low</td><td align="char" char="." valign="bottom">48</td><td align="char" char="." valign="bottom">13</td><td align="char" char="." valign="bottom">5</td><td align="char" char="." valign="bottom">0</td></tr></tbody></table></table-wrap></sec><sec id="s3-2"><title>Validation/confirmation multi-institutional cohort</title><p>For the analysis of a second multi-institutional validation/confirmation and expansion prostate cancer cohort from TCGA, patient clinical data (<xref ref-type="table" rid="table4">Table 4</xref>) and gene expression data were available on men with prostate cancer (n=497). Gene expression data from nonneoplastic prostatic tissue (hereafter termed ‘normal prostate’) were also available in 52 (10.5%) of the cases. The basis for the cohort has been described previously (<xref ref-type="bibr" rid="bib6">Cancer Genome Atlas Research Network, 2015</xref>). Briefly, the cohort comprised men whose ages ranged from 41 to 78 years, and who had a radical prostatectomy for primary prostate cancer. The distribution of prostate cancer grades was as follows: Gleason Score 3+3 = 6 (Grade Group 1), 9.0%; Gleason Scores 3+4 = 7 or 4+3 = 7 (Grade Groups 2 and 3), 49.7%; Gleason Score 4+4 = 8 (Grade Group 4), 12.9%; and Gleason Scores 4+5 = 9 or 5+4 = 9, 27.6%; and 5+5 = 10 (Grade Group 5), 0.8%. For pathological stage, most tumors were pT2c (33%), pT3a (32%), or pT3b (27%), with a small fraction being pT4 (2%). Data on disease recurrence were available for 429 men (86.3%), with 58 (11.7% [13.5% of those with follow-up information available]) having biochemical recurrence.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Validation cohort: clinicopathological features of the 497 patients in the prostate cancer TCGA dataset, with a total of 549 tissue samples included.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Variable</th><th align="left" valign="bottom">Number</th><th align="left" valign="bottom">% or Mean (STD; range)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Age (years)</td><td align="left" valign="bottom">497</td><td align="left" valign="bottom">61 (6.8; 41–78)</td></tr><tr><td align="left" valign="bottom">Vital status</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Alive</td><td align="left" valign="bottom">487</td><td align="left" valign="bottom">97.9</td></tr><tr><td align="left" valign="bottom"> Dead</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">2.1</td></tr><tr><td align="left" valign="bottom" colspan="3">Sample type</td></tr><tr><td align="left" valign="bottom"> Primary tumor</td><td align="left" valign="bottom">497</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"> Normal (non-malignant) prostate</td><td align="left" valign="bottom">52</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="3">Post-prostatectomy Gleason Grade (Grade Group)</td></tr><tr><td align="char" char="." valign="bottom"> 6 (Grade Group 1)</td><td align="left" valign="bottom">45</td><td align="left" valign="bottom">9</td></tr><tr><td align="left" valign="bottom"> 7 (Grade Groups 2 and 3)</td><td align="left" valign="bottom">247</td><td align="left" valign="bottom">49.7</td></tr><tr><td align="char" char="." valign="bottom"> 8 (Grade Group 4)</td><td align="left" valign="bottom">64</td><td align="left" valign="bottom">12.9</td></tr><tr><td align="char" char="." valign="bottom"> 9 (Grade Group 5)</td><td align="left" valign="bottom">137</td><td align="left" valign="bottom">27.6</td></tr><tr><td align="char" char="." valign="bottom"> 10 (Grade Group 5)</td><td align="left" valign="bottom">4</td><td align="left" valign="bottom">0.8</td></tr><tr><td align="left" valign="bottom" colspan="3">Pathological stage</td></tr><tr><td align="left" valign="bottom"> pT2a</td><td align="left" valign="bottom">13</td><td align="left" valign="bottom">2.6</td></tr><tr><td align="left" valign="bottom"> pT2b</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">2</td></tr><tr><td align="left" valign="bottom"> pT2c</td><td align="left" valign="bottom">164</td><td align="left" valign="bottom">33</td></tr><tr><td align="left" valign="bottom"> pT3a</td><td align="left" valign="bottom">158</td><td align="left" valign="bottom">32</td></tr><tr><td align="left" valign="bottom"> pT3b</td><td align="left" valign="bottom">135</td><td align="left" valign="bottom">27</td></tr><tr><td align="left" valign="bottom"> pT4</td><td align="left" valign="bottom">10</td><td align="left" valign="bottom">2</td></tr><tr><td align="left" valign="bottom"> Unknown</td><td align="left" valign="bottom">7</td><td align="left" valign="bottom">1.4</td></tr><tr><td align="left" valign="bottom" colspan="3">Biochemical recurrence status</td></tr><tr><td align="left" valign="bottom"> No</td><td align="left" valign="bottom">371</td><td align="left" valign="bottom">74.6</td></tr><tr><td align="left" valign="bottom"> Yes</td><td align="left" valign="bottom">58</td><td align="left" valign="bottom">11.7</td></tr><tr><td align="left" valign="bottom"> Unknown</td><td align="left" valign="bottom">68</td><td align="left" valign="bottom">13.7</td></tr></tbody></table><table-wrap-foot><fn><p>STD, standard deviation.</p></fn></table-wrap-foot></table-wrap><p>We compared gene expression levels (RSEM) in prostatic adenocarcinoma to those in normal prostate samples in the dataset from TCGA (<xref ref-type="fig" rid="fig3">Figure 3A</xref>): <italic>PCA3</italic> had significantly increased expression in carcinoma (median: 12.4; interquartile range [IQR]: 10.3–13.7) as compared with normal prostate (median: 6.9; IQR: 5.2–9.6, [p-value &lt;0.001]), and <italic>PRUNE2</italic> showed simultaneous lower expression in carcinoma (median: 11.4; IQR: 10.7–12.0) versus normal prostate (median: 12.2; IQR: 11.8–12.6, [p-value &lt;0.001]). As depicted in <xref ref-type="fig" rid="fig3">Figure 3B</xref>, comparing tumor gene expression across different prostate cancer pathological grades, <italic>PCA3</italic> expression was significantly lower in tumors with Gleason Score greater than 7 (median: 11.6; IQR: 8.4–13.4) than in tumors with Gleason Score 7 (median: 12.8; IQR: 11.3–13.8, [p-value &lt;0.001]) or less than 7 (median: 12.5; IQR: 11.8–13.7, [p-value = 0.01]). <italic>PRUNE2</italic> showed a small decrease in expression in tumors with Gleason Score greater than 7 (median: 11.3; IQR: 10.4–11.9) as compared with tumors with Gleason Score 7 (median: 11.5; IQR: 10.8–12.1, [p-value = 0.014]) or less than 7 (median: 11.6; IQR: 11.0–12.1, [p-value = 0.049]). As shown in <xref ref-type="fig" rid="fig3">Figure 3C</xref>, comparing tumor gene expression across different tumor pathological stages, <italic>PCA3</italic> expression was higher in pT2 tumors (median: 12.6; IQR: 11.2–13.8) than in tumors that were pT3 (median: 12.2; IQR: 9.7–13.6, [p-value = 0.01]) or pT4 (median: 12.1; IQR: 9.6–12.7, [p-value = 0.61]). There was no significant difference (p-value &gt;0.05) between <italic>PRUNE2</italic> expression levels between the different tumor stages: pT2 (median: 11.4; IQR: 10.7–12.1), pT3 (median: 11.3; IQR: 10.6–12.0), and pT4 (median: 11.7; IQR: 10.8–12.1). We also found that the ratio of <italic>PCA3/PRUNE2</italic> expression showed similar associations with Gleason Score and pathological stage as were seen with <italic>PCA3</italic> expression (data not shown). Overall, despite the differences in gene expression among tumor grades and stages, the median expression of <italic>PCA3</italic> was significantly higher in all tumor grades and stages than the expression of <italic>PCA3</italic> in normal prostate, and, inversely, the median expression of <italic>PRUNE2</italic> in all tumor grades and stages was significantly less than the expression of <italic>PRUNE2</italic> in normal prostate.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Analyses of TCGA prostate cancer validation cohort.</title><p>(<bold>A</bold>) <italic>PCA3</italic> and <italic>PRUNE2</italic> expression in nonneoplastic prostatic glandular tissue and in prostatic adenocarcinoma in the TCGA cohort illustrating consistent gene expression differences between tumor (n=497) and nonneoplastic (n=52) prostate in both cohorts. (<bold>B, C</bold>) <italic>PCA3</italic> expression in the cohort from TCGA (n=497) across Gleason grades (<bold>B</bold>) showing lower expression in higher grade (&gt;7) tumors and across tumor stages (<bold>C</bold>) showing lower expression in higher stage tumors. All illustrated tumor grades and stages show higher expression than nonneoplastic prostatic epithelium. (<bold>D</bold>) <italic>PCA3</italic> expression in patients without versus with biochemical recurrence in the TCGA cohort (n=429). In the TCGA cohort, lower <italic>PCA3</italic> median expression was associated with biochemical recurrence. Box plots of gene expression in the TCGA cohort is reported as log<sub>2</sub>RSEM data. The horizontal line within each box represents the median value, while the box represents the interquartile range, and the whiskers extend out to 1.5 times the interquartile range. Outliers are represented by circles. p-Values are noted for the indicated comparisons. RSEM: RNA-Seq by Expectation-Maximization.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81929-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Validation cohort – no significant difference in tumor <italic>PRUNE2</italic> expression by biochemical recurrence status.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81929-fig3-figsupp1-v3.tif"/></fig></fig-group><p>As shown for the discovery cohort, we also evaluated the relationship between PCA3 and PRUNE2 expression levels and recurrence status. We found that patients who had biochemical recurrence after prostatectomy had significantly lower tumor expression levels of <italic>PCA3</italic> (median, 11.58; IQR, 8.28–13.14) than those who did not recur (12.51; 10.64–13.71, [p-value &lt;0.01]; <xref ref-type="fig" rid="fig3">Figure 3D</xref>). However, we did not see an association between tumor <italic>PCA3</italic> expression and biochemical recurrence on multivariable Cox proportional hazards modeling when adjusting for tumor grade, stage, and age at diagnosis (HR, 0.96; 95% CI, 0.87–1.04, [p-value = 0.36]), as presented in Appendix 1 and <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>. We did not see a significant association between <italic>PRUNE2</italic> expression in those patients that had biochemical recurrence as compared with those patients who did not recur (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Here, we assessed the tumor and control adjacent normal prostatic glandular tissue expression of the lncRNA <italic>PCA3</italic> and the protein-coding <italic>PRUNE2</italic> gene in two independent retrospective cohorts of patients with primary organ-confined prostate cancer after treatment by radical prostatectomy (<xref ref-type="fig" rid="fig4">Figure 4</xref>). As compared with normal prostate, we found that prostate cancer showed consistent increased expression of <italic>PCA3</italic> and consistent decreased expression of <italic>PRUNE2</italic> in tumors across a broad range of pathological attributes (i.e., Gleason grades, scores, groups, and stages) in both patient cohorts. Although the magnitude of the change of expression between normal and tumor appears greater for <italic>PCA3</italic> than for <italic>PRUNE2</italic> in both cohorts (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig3">Figure 3A</xref>), we attribute this to the reciprocal nature of the comparison, in conjunction with the very low level of normal prostatic <italic>PCA3</italic> expression as compared with the higher expression of <italic>PRUNE2</italic> in normal prostate. Overall, the findings support the mechanistic role of a tumor-specific molecular axis in which <italic>PCA3</italic> acts as dominant-negative oncogene and <italic>PRUNE2</italic> as a tumor suppressor gene in human prostate cancer and indicate that the interplay between these genes is dysregulated early in prostate cancer.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Graphical summary of the analyses.</title><p><italic>PCA3</italic> and <italic>PRUNE2</italic> gene expression relationship in paired prostate cancer and adjacent normal prostate was analyzed in two independent retrospective cohorts of clinically annotated cases post-radical prostatectomy: a single-institutional discovery cohort (n=107; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) and a multi-institutional validation cohort (n=497). We also serially examined clinical/pathological variables including time to disease recurrence. Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81929-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Flow diagram of discovery cohort selection criteria and clinicopathological characteristics available.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81929-fig4-figsupp1-v3.tif"/></fig></fig-group><p>Specifically, when we compared <italic>PCA3</italic> expression in the validation cohort from TCGA, although average expression in all grades, stages, and groups was higher than in normal prostate, we found that among tumors there was significantly decreased <italic>PCA3</italic> expression in tumors with higher grades (Gleason Score &gt;7) and in higher stages (&gt;pT2), as compared with lower grades, stages, or groups, respectively. These paradoxical findings are consistent with several early studies (<xref ref-type="bibr" rid="bib25">Salagierski et al., 2010</xref>; <xref ref-type="bibr" rid="bib4">Balcerczak et al., 2003</xref>) and in particular with a recent tissue-based study of <italic>PCA3</italic> expression in prostate cancer (<xref ref-type="bibr" rid="bib2">Alshalalfa et al., 2017</xref>). In that large cohort study, lower levels of tumor <italic>PCA3</italic> in both biopsy and radical prostatectomy specimens were associated with high-grade tumors, and in radical prostatectomy specimens decreased <italic>PCA3</italic> expression was associated with features of higher stages. Based on these results, it has been proposed that <italic>PCA3</italic> might actually represent a differentiation marker in human prostate cancer (<xref ref-type="bibr" rid="bib2">Alshalalfa et al., 2017</xref>). The finding of decreasing <italic>PCA3</italic> expression with increasing tumor grades and stages in both our study and others is broadly consistent with another previous study (<xref ref-type="bibr" rid="bib24">Reis et al., 2004</xref>), which found that the class of antisense intronic RNAs was markedly over-represented among the top transcripts associated with tumor differentiation in human prostate cancer. The finding of an inverse association between <italic>PCA3</italic> expression and increasing grades and stages may also relate to links between <italic>PCA3</italic> expression and androgen receptor (AR) signaling and the likelihood of <italic>PCA3</italic> having an important role in the early steps of prostate cancer carcinogenesis, with a reduced role when the disease is more advanced. Indeed, previous work by our own group and by others indicates that <italic>PCA3</italic> is upregulated by AR signaling (<xref ref-type="bibr" rid="bib29">Teixeira et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Ferreira et al., 2012</xref>; <xref ref-type="bibr" rid="bib26">Salameh et al., 2015</xref>), and that <italic>PCA3</italic> is also involved in modulating AR signaling (<xref ref-type="bibr" rid="bib11">Ferreira et al., 2012</xref>; <xref ref-type="bibr" rid="bib16">Lemos et al., 2016</xref>). Interestingly, it has also been shown in vitro that <italic>PCA3</italic> silencing sensitizes prostate cancer cells to enzalutamide-induced decreased cell growth (<xref ref-type="bibr" rid="bib23">Özgür et al., 2017</xref>). <xref ref-type="bibr" rid="bib2">Alshalalfa et al., 2017</xref>, suggest that because low pretreatment serum testosterone levels are associated with diseases with higher grades and stages, and because of the relationship between AR signaling and <italic>PCA3</italic> expression, therefore lower <italic>PCA3</italic> expression may reflect the lower serum testosterone in these patients. However, we do not have any data on the pretreatment serum concentration of testosterone and other androgens, and we are not able to test that hypothesis in this study.</p><p>Because prostate cancers, especially Gleason Score 7 (Grade Groups 2 and 3) tumors, are quite frequent (about half of the total cases) and show divergent clinical behavior, there is great interest in developing prognostic biomarkers for risk stratification. Studies on the association of <italic>PCA3</italic> expression levels with outcome and prognosis show conflicting results (<xref ref-type="bibr" rid="bib20">Loeb and Partin, 2011</xref>), and unlike this present study, most prior reports are based on urinary <italic>PCA3</italic> expression (<xref ref-type="bibr" rid="bib21">Loeb et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Lemos et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Fenstermaker et al., 2017</xref>). Our exploration of the validation cohort from TCGA, which comprised a wide spectrum of tumor grades and stages, revealed an association between lower levels of tumor <italic>PCA3</italic> expression and biochemical recurrence; however, this association was not found after taking grade and stage into account. This finding makes sense, as increasing grade and stage are both variables that are associated with lower <italic>PCA3</italic> expression. In their tissue-based cohort, <xref ref-type="bibr" rid="bib2">Alshalalfa et al., 2017</xref>, also found an association between low <italic>PCA3</italic> levels and adverse outcomes, including biochemical recurrence, metastasis, and prostate cancer-specific mortality; however, it is not clear whether such findings are independent of clinical and pathological variables (such as Gleason grade, stage, and group), as a multivariable analysis was not reported. Nevertheless, the demonstration of an (unadjusted) association between <italic>PCA3</italic> levels and outcome may have potential relevance in the liquid biopsy setting. For the discovery cohort of patients, we selected organ-confined, intermediate-risk tumors (Gleason Grade Groups 2 and 3, with tumor stages pT2 and pT3) where prognostic information might be expected to be most helpful clinically, to test for an association with outcome. We did not see any association between tumor <italic>PCA3</italic> expression and biochemical recurrence in this particular grade and stage setting.</p><p><italic>PRUNE2</italic>, a human homolog of the <italic>Drosophila prune</italic> gene, encodes for a protein with BCH, DHHA2, and PPX1 functional domains (<xref ref-type="bibr" rid="bib11">Ferreira et al., 2012</xref>). The BCH domain can inhibit the Rho family of proteins, small GTPases with roles in cell transformation, migration and metastasis, and cell cycle progression (<xref ref-type="bibr" rid="bib8">Clarke et al., 2009</xref>; <xref ref-type="bibr" rid="bib15">Iwama et al., 2011</xref>). Evidence is accumulating that <italic>PRUNE2</italic> might act as a tumor suppressor gene. Loss-of-function mutations have been described in several tumor types, including germline and somatic mutations in parathyroid cancer (<xref ref-type="bibr" rid="bib33">Yu et al., 2015</xref>) and somatic mutations in solid papillary carcinoma (<xref ref-type="bibr" rid="bib1">Alsadoun et al., 2018</xref>), while high expression of PRUNE2 protein correlates with favorable prognosis in neuroblastoma (<xref ref-type="bibr" rid="bib22">Machida et al., 2006</xref>). Others have shown evidence of inactivating <italic>PRUNE2</italic> mutations in Merkel cell carcinoma (<xref ref-type="bibr" rid="bib14">Harms et al., 2015</xref>) and that the restoration of downregulated PRUNE2 in oral cancer suppresses tumor cell migration (<xref ref-type="bibr" rid="bib28">Su et al., 2021</xref>), further supporting the role of <italic>PRUNE2</italic> as a tumor suppressor. In prostate cancer, the evidence is limited and controversial: an early report found that <italic>PRUNE2</italic> expression was upregulated in prostate cancer and metastases in a small number of samples, and was androgen-inducible in prostate cancer cells (<xref ref-type="bibr" rid="bib8">Clarke et al., 2009</xref>). However, a subsequent study on a larger number of samples found that <italic>PRUNE2</italic> expression either decreased or did not increase in aggressive prostate cancer, and that <italic>PRUNE2</italic> expression was not androgen-inducible (<xref ref-type="bibr" rid="bib25">Salagierski et al., 2010</xref>). While this work was under external peer-review, Cardoso et al. have shown that <italic>PRUNE2</italic> is a prostate cancer predisposition gene, which is consistent with our results and interpretations (<xref ref-type="bibr" rid="bib7">Cardoso et al., 2022</xref>).</p><p>Altogether, the findings in the current study provide additional support for our previous findings (<xref ref-type="bibr" rid="bib26">Salameh et al., 2015</xref>) that <italic>PRUNE2</italic> acts as a functional tumor suppressor gene in human prostate cancer. Here, we described consistently lower expression of <italic>PRUNE2</italic> in prostate cancers of all grades and stages as compared to normal prostate. The findings in our present study are also consistent with the negative regulation of <italic>PRUNE2</italic> by <italic>PCA3</italic> in prostate cancer. We found no significant differences in <italic>PRUNE2</italic> expression across tumor stage, and only a small decrease in expression with increasing tumor grade, suggesting that loss of <italic>PRUNE2</italic> tumor suppressor activity is an early molecular event in prostate cancer. We are not aware of any prior reports of the prognostic significance of tumor <italic>PRUNE2</italic> expression in prostate cancer but, at least in this retrospective study of two independent prostate cancer patient cohorts, we did not find any association between <italic>PRUNE2</italic> expression and biochemical outcomes.</p><p>Strengths of this study include that broadly consistent findings were described in the two independent well-characterized clinically annotated primary prostate cancer cohorts used for analysis, and that the findings were robust across multiple assays in the discovery patient cohort and between the different methods of measurement of gene expression used in the two cohorts. The assessment of <italic>PCA3</italic> expression directly and specifically in tissue (as opposed to urine) is a novelty and a strength as our primary goal was the study of the <italic>PRUNE2/PCA3</italic> regulatory axis in human prostate cancer. We reasoned that the study of tissue expression is likely more informative of tumor biology than traditional urinalysis, not least of all because urinary expression, though very well characterized, could by subject to potential confounding issues such as RNA stability in urine or the contribution of differential urinary shedding. However, from the standpoint of assessment of prognostic information, a drawback of analyzing tissue <italic>PCA3</italic> expression is that the results are not directly comparable to the multiple previous studies that measured urinary <italic>PCA3</italic> scores and ultimately led to FDA and EMA approval for clinical applications in the US and EU. Moreover, while we did find consistent findings with a large tissue cohort study relating <italic>PCA3</italic> expression and biochemical recurrence (<xref ref-type="bibr" rid="bib2">Alshalalfa et al., 2017</xref>), the analysis presented here was limited in its ability to unequivocally determine the prognostic value of <italic>PCA3</italic> and <italic>PRUNE2</italic> expression as the overall proportion of patients with biochemical recurrences was relatively low. Finally, we were not able to fully address the relationship of reciprocal gene expression of <italic>PCA3</italic> and <italic>PRUNE2</italic> to the outcomes of metastases and prostate cancer-specific deaths, again due to the relative paucity of these events.</p><p>In conclusion, we found consistent upregulation of <italic>PCA3</italic> and downregulation of <italic>PRUNE2</italic> in prostate cancer as compared with normal prostate in two retrospective and independent patient cohorts (summarized in <xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), supporting that <italic>PCA3</italic> and <italic>PRUNE2</italic> function as an oncogene and a tumor suppressor gene, respectively, in human prostate cancer. The inverse correlation of <italic>PCA3</italic> and <italic>PRUNE2</italic> expression is consistent with our prior findings of a functional interplay between the two genes as part of a unique regulatory unit functioning at a single genetic locus in prostate cancer cells with <italic>PCA3</italic> negatively downregulating <italic>PRUNE2</italic> expression (<xref ref-type="bibr" rid="bib26">Salameh et al., 2015</xref>). The mechanistic dysregulation of <italic>PCA3</italic> and <italic>PRUNE2</italic> is observed across the spectrum of tumor grades and stages, suggesting that this is an early and stable molecular event in prostate cancer. On the other hand, we have not detected any regulatory effects of <italic>PRUNE2/PCA3</italic> in late genetic events such as prostate cancer progressing to biochemical recurrence, which includes the development of local tumor recurrence and/or the development of metastatic disease. The findings presented here represent additional evidence for the functional reciprocal co-regulation of <italic>PCA3</italic> and <italic>PRUNE2</italic> in the setting of early tumorigenesis but not in late events in human prostate cancer. Taken together along with the well-documented specificity of <italic>PCA3</italic> overexpression, our findings establish the <italic>PCA3</italic>/<italic>PRUNE2</italic> regulatory axis as an attractive early molecular target candidate for intervention in the therapy of human prostate cancer.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>The University of New Mexico filed patent applications on PRUNE2- related technology, for which Diana Nunes was an inventor (inventors: DNN, EDN, RP, and WA). Those applications were briefly optioned by MBrace Therapeutics, but the applications have since been abandoned and the agreements terminated. No payments were made to Diana Nunes, and the author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>The University of New Mexico filed patent applications on PRUNE2- related technology, for which Emmanuel Dias-Neto was an inventor (inventors: DNN, EDN, RP, and WA). Those applications were briefly optioned by MBrace Therapeutics, but the applications have since been abandoned and the agreement terminated. No payments were made to Emmanuel Dias-Neto, and the author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf4"><p>serves as the Chief Executive Officer of MBrace Therapeutics. Mbrace did not provide financial support for the present work</p></fn><fn fn-type="COI-statement" id="conf5"><p>is a founder and shareholder of Interleukin Combinatorial Therapies, Inc, InVaMet, Inc, and io9, LLC; none of these companies provided funds or participated in the present work. These arrangements are managed in accordance with the established institutional conflict of interest policies for the respective institution. The author received support for attending the Aspen Cancer Conference, and participated in a Leadership or fiduciary role. The author holds a Leadership or fiduciary role at Genetron Health for which they receive board fees, and are on the Board of Directors for the GBM AGILE Clinical Trial. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf6"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con16"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing – original draft</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Writing – original draft</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: For the discovery cohort, there was University of New Mexico Health Sciences Institutional Review Board (IRB) approval (HRRC15-138), and the study was carried out in accordance with the United States Common Rule. As the discovery cohort involved secondary use of archival biospecimens, the IRB waived the requirement for informed consent .</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81929-mdarchecklist1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><caption><title>STROBE Checklist.</title></caption><media xlink:href="elife-81929-repstand1-v3.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>R code and SAS code of descriptive statistics.</title></caption><media xlink:href="elife-81929-code1-v3.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>For the discovery cohort, all data generated or analyzed are included in the manuscript and source data files, except for patient-level ethnicity data. Patient-level ethnicity data is not included due to the potential for identifiability. However detailed summary ethnicity data is presented in the manuscript and in Table 1. Requests to access the patient level ethnicity data should be directed to the corresponding author with a project proposal. Source codes are also available in the supplemental source code file. For the Validation Cohort, clinicopathological patient characteristics and gene level transcription data from The Cancer Genome Atlas (TCGA) were accessed from the UCSC Xena Resource.</p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><collab>University of North Carolina TCGA genome characterization center</collab></person-group><year iso-8601-date="2017">2017</year><data-title>TCGA prostate adenocarcinoma (PRAD) gene expression by RNAseq (polyA+ IlluminaHiSeq)</data-title><source>TCGA Prostate Cancer (PRAD) TCGA.PRAD.sampleMap/HiSeqV2</source><pub-id pub-id-type="accession" xlink:href="https://xenabrowser.net/datapages/?dataset=TCGA.PRAD.sampleMap%2FHiSeqV2&amp;host=https%3A%2F%2Ftcga.xenahubs.net&amp;removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443">20,531</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We received support from the Human Tissue Repository and Tissue Analysis Shared Resource from the Department of Pathology of the University of New Mexico School of Medicine and a pilot award from the UNMCCC. RP and WA were supported by awards from the Levy-Longenbaugh Donor-Advised Fund and the Prostate Cancer Foundation. EDN reports research fellowship support from the Brazilian National Council for Scientific and Technological Development (CNPq), Brazil, and the Associação Beneficente Alzira Denise Hertzog Silva (ABADHS), Brazil. This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the UNMCCC (CA118100) and the Rutgers Cancer Institute of New Jersey (CA072720). The results shown here are in part based upon data generated by the TCGA Research Network: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/tcga">https://www.cancer.gov/tcga</ext-link>. These data have been presented in part at the 2017 American Society of Clinical Oncology Annual Meeting.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsadoun</surname><given-names>N</given-names></name><name><surname>MacGrogan</surname><given-names>G</given-names></name><name><surname>Truntzer</surname><given-names>C</given-names></name><name><surname>Lacroix-Triki</surname><given-names>M</given-names></name><name><surname>Bedgedjian</surname><given-names>I</given-names></name><name><surname>Koeb</surname><given-names>M-H</given-names></name><name><surname>El Alam</surname><given-names>E</given-names></name><name><surname>Medioni</surname><given-names>D</given-names></name><name><surname>Parent</surname><given-names>M</given-names></name><name><surname>Wuithier</surname><given-names>P</given-names></name><name><surname>Robert</surname><given-names>I</given-names></name><name><surname>Boidot</surname><given-names>R</given-names></name><name><surname>Arnould</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases</article-title><source>Modern Pathology</source><volume>31</volume><fpage>1367</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1038/s41379-018-0047-1</pub-id><pub-id pub-id-type="pmid">29785016</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alshalalfa</surname><given-names>M</given-names></name><name><surname>Verhaegh</surname><given-names>GW</given-names></name><name><surname>Gibb</surname><given-names>EA</given-names></name><name><surname>Santiago-Jiménez</surname><given-names>M</given-names></name><name><surname>Erho</surname><given-names>N</given-names></name><name><surname>Jordan</surname><given-names>J</given-names></name><name><surname>Yousefi</surname><given-names>K</given-names></name><name><surname>Lam</surname><given-names>LLC</given-names></name><name><surname>Kolisnik</surname><given-names>T</given-names></name><name><surname>Chelissery</surname><given-names>J</given-names></name><name><surname>Seiler</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>AE</given-names></name><name><surname>Karnes</surname><given-names>RJ</given-names></name><name><surname>Schaeffer</surname><given-names>EM</given-names></name><name><surname>Lotan</surname><given-names>TT</given-names></name><name><surname>Den</surname><given-names>RB</given-names></name><name><surname>Freedland</surname><given-names>SJ</given-names></name><name><surname>Davicioni</surname><given-names>E</given-names></name><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients</article-title><source>Oncotarget</source><volume>8</volume><fpage>50804</fpage><lpage>50813</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15133</pub-id><pub-id pub-id-type="pmid">28881605</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arun</surname><given-names>G</given-names></name><name><surname>Diermeier</surname><given-names>SD</given-names></name><name><surname>Spector</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Therapeutic targeting of long non-coding rnas in cancer</article-title><source>Trends in Molecular Medicine</source><volume>24</volume><fpage>257</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2018.01.001</pub-id><pub-id pub-id-type="pmid">29449148</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balcerczak</surname><given-names>E</given-names></name><name><surname>Mirowski</surname><given-names>M</given-names></name><name><surname>Sasor</surname><given-names>A</given-names></name><name><surname>Wierzbicki</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Expression of p65, DD3 and c-erbb2 genes in prostate cancer</article-title><source>Neoplasma</source><volume>50</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">12740642</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussemakers</surname><given-names>MJ</given-names></name><name><surname>van Bokhoven</surname><given-names>A</given-names></name><name><surname>Verhaegh</surname><given-names>GW</given-names></name><name><surname>Smit</surname><given-names>FP</given-names></name><name><surname>Karthaus</surname><given-names>HF</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name><name><surname>Debruyne</surname><given-names>FM</given-names></name><name><surname>Ru</surname><given-names>N</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>DD3: a new prostate-specific gene, highly overexpressed in prostate cancer</article-title><source>Cancer Research</source><volume>59</volume><fpage>5975</fpage><lpage>5979</lpage><pub-id pub-id-type="pmid">10606244</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular taxonomy of primary prostate cancer</article-title><source>Cell</source><volume>163</volume><fpage>1011</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.025</pub-id><pub-id pub-id-type="pmid">26544944</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>M</given-names></name><name><surname>Maia</surname><given-names>S</given-names></name><name><surname>Brandão</surname><given-names>A</given-names></name><name><surname>Sahasrabudhe</surname><given-names>R</given-names></name><name><surname>Lott</surname><given-names>P</given-names></name><name><surname>Belter</surname><given-names>N</given-names></name><name><surname>Carvajal-Carmona</surname><given-names>LG</given-names></name><name><surname>Paulo</surname><given-names>P</given-names></name><name><surname>Teixeira</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene</article-title><source>British Journal of Cancer</source><pub-id pub-id-type="doi">10.1038/s41416-022-02125-6</pub-id><pub-id pub-id-type="pmid">36564567</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>RA</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>AY</given-names></name><name><surname>Roper</surname><given-names>K</given-names></name><name><surname>Teng</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>ZM</given-names></name><name><surname>Samaratunga</surname><given-names>H</given-names></name><name><surname>Lavin</surname><given-names>MF</given-names></name><name><surname>Gardiner</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e4995</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004995</pub-id><pub-id pub-id-type="pmid">19319183</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Kok</surname><given-names>JB</given-names></name><name><surname>Verhaegh</surname><given-names>GW</given-names></name><name><surname>Roelofs</surname><given-names>RW</given-names></name><name><surname>Hessels</surname><given-names>D</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Aalders</surname><given-names>TW</given-names></name><name><surname>Swinkels</surname><given-names>DW</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>DD3(PCA3), a very sensitive and specific marker to detect prostate tumors</article-title><source>Cancer Research</source><volume>62</volume><fpage>2695</fpage><lpage>2698</lpage><pub-id pub-id-type="doi">10.1016/S1569-9056(02)80019-7</pub-id><pub-id pub-id-type="pmid">11980670</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenstermaker</surname><given-names>M</given-names></name><name><surname>Mendhiratta</surname><given-names>N</given-names></name><name><surname>Bjurlin</surname><given-names>MA</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Rosenkrantz</surname><given-names>AB</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Deng</surname><given-names>F-M</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name><name><surname>Lepor</surname><given-names>H</given-names></name><name><surname>Taneja</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Risk stratification by urinary prostate cancer gene 3 testing before magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy among men with no history of biopsy</article-title><source>Urology</source><volume>99</volume><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2016.08.022</pub-id><pub-id pub-id-type="pmid">27562202</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>LB</given-names></name><name><surname>Palumbo</surname><given-names>A</given-names></name><name><surname>de Mello</surname><given-names>KD</given-names></name><name><surname>Sternberg</surname><given-names>C</given-names></name><name><surname>Caetano</surname><given-names>MS</given-names></name><name><surname>de Oliveira</surname><given-names>FL</given-names></name><name><surname>Neves</surname><given-names>AF</given-names></name><name><surname>Nasciutti</surname><given-names>LE</given-names></name><name><surname>Goulart</surname><given-names>LR</given-names></name><name><surname>Gimba</surname><given-names>ERP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling</article-title><source>BMC Cancer</source><volume>12</volume><elocation-id>507</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-12-507</pub-id><pub-id pub-id-type="pmid">23130941</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>MJ</given-names></name><name><surname>Craft</surname><given-names>B</given-names></name><name><surname>Hastie</surname><given-names>M</given-names></name><name><surname>Repečka</surname><given-names>K</given-names></name><name><surname>McDade</surname><given-names>F</given-names></name><name><surname>Kamath</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Rogers</surname><given-names>D</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Visualizing and interpreting cancer genomics data via the xena platform</article-title><source>Nature Biotechnology</source><volume>38</volume><fpage>675</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0546-8</pub-id><pub-id pub-id-type="pmid">32444850</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordetsky</surname><given-names>J</given-names></name><name><surname>Epstein</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Grading of prostatic adenocarcinoma: current state and prognostic implications</article-title><source>Diagnostic Pathology</source><volume>11</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.1186/s13000-016-0478-2</pub-id><pub-id pub-id-type="pmid">26956509</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>PW</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Verhaegen</surname><given-names>ME</given-names></name><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Palanisamy</surname><given-names>N</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Fullen</surname><given-names>DR</given-names></name><name><surname>Bichakjian</surname><given-names>CK</given-names></name><name><surname>Johnson</surname><given-names>TM</given-names></name><name><surname>Dlugosz</surname><given-names>AA</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The distinctive mutational spectra of polyomavirus-negative merkel cell carcinoma</article-title><source>Cancer Research</source><volume>75</volume><fpage>3720</fpage><lpage>3727</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0702</pub-id><pub-id pub-id-type="pmid">26238782</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwama</surname><given-names>E</given-names></name><name><surname>Tsuchimoto</surname><given-names>D</given-names></name><name><surname>Iyama</surname><given-names>T</given-names></name><name><surname>Sakumi</surname><given-names>K</given-names></name><name><surname>Nakagawara</surname><given-names>A</given-names></name><name><surname>Takayama</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name><name><surname>Nakabeppu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cancer-related PRUNE2 protein is associated with nucleotides and is highly expressed in mature nerve tissues</article-title><source>Journal of Molecular Neuroscience</source><volume>44</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1007/s12031-010-9490-2</pub-id><pub-id pub-id-type="pmid">21234814</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemos</surname><given-names>AEG</given-names></name><name><surname>Ferreira</surname><given-names>LB</given-names></name><name><surname>Batoreu</surname><given-names>NM</given-names></name><name><surname>de Freitas</surname><given-names>PP</given-names></name><name><surname>Bonamino</surname><given-names>MH</given-names></name><name><surname>Gimba</surname><given-names>ERP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PCA3 long noncoding RNA modulates the expression of key cancer-related genes in lncap prostate cancer cells</article-title><source>Tumour Biology</source><volume>37</volume><fpage>11339</fpage><lpage>11348</lpage><pub-id pub-id-type="doi">10.1007/s13277-016-5012-3</pub-id><pub-id pub-id-type="pmid">26960690</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemos</surname><given-names>AEG</given-names></name><name><surname>Matos</surname><given-names>A</given-names></name><name><surname>Ferreira</surname><given-names>LB</given-names></name><name><surname>Gimba</surname><given-names>ERP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The long non-coding RNA pca3: an update of its functions and clinical applications as a biomarker in prostate cancer</article-title><source>Oncotarget</source><volume>10</volume><fpage>6589</fpage><lpage>6603</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27284</pub-id><pub-id pub-id-type="pmid">31762940</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Dewey</surname><given-names>CN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-323</pub-id><pub-id pub-id-type="pmid">21816040</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>S</given-names></name><name><surname>Partin</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Review of the literature: PCA3 for prostate cancer risk assessment and prognostication</article-title><source>Reviews in Urology</source><volume>13</volume><elocation-id>e191-5</elocation-id><pub-id pub-id-type="pmid">22232568</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>S</given-names></name><name><surname>Bruinsma</surname><given-names>SM</given-names></name><name><surname>Nicholson</surname><given-names>J</given-names></name><name><surname>Briganti</surname><given-names>A</given-names></name><name><surname>Pickles</surname><given-names>T</given-names></name><name><surname>Kakehi</surname><given-names>Y</given-names></name><name><surname>Carlsson</surname><given-names>SV</given-names></name><name><surname>Roobol</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification</article-title><source>European Urology</source><volume>67</volume><fpage>619</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2014.10.010</pub-id><pub-id pub-id-type="pmid">25457014</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machida</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Ooo</surname><given-names>ML</given-names></name><name><surname>Ohira</surname><given-names>M</given-names></name><name><surname>Isogai</surname><given-names>E</given-names></name><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Hirato</surname><given-names>J</given-names></name><name><surname>Tomotsune</surname><given-names>D</given-names></name><name><surname>Hirata</surname><given-names>T</given-names></name><name><surname>Fujimori</surname><given-names>M</given-names></name><name><surname>Adachi</surname><given-names>W</given-names></name><name><surname>Nakagawara</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and cdc42gap homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas</article-title><source>Oncogene</source><volume>25</volume><fpage>1931</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209225</pub-id><pub-id pub-id-type="pmid">16288218</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Özgür</surname><given-names>E</given-names></name><name><surname>Celik</surname><given-names>AI</given-names></name><name><surname>Darendeliler</surname><given-names>E</given-names></name><name><surname>Gezer</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>PCA3</italic> silencing sensitizes prostate cancer cells to enzalutamide-mediated androgen receptor blockade</article-title><source>Anticancer Research</source><volume>37</volume><fpage>3631</fpage><lpage>3637</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11733</pub-id><pub-id pub-id-type="pmid">28668854</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>EM</given-names></name><name><surname>Nakaya</surname><given-names>HI</given-names></name><name><surname>Louro</surname><given-names>R</given-names></name><name><surname>Canavez</surname><given-names>FC</given-names></name><name><surname>Flatschart</surname><given-names>AVF</given-names></name><name><surname>Almeida</surname><given-names>GT</given-names></name><name><surname>Egidio</surname><given-names>CM</given-names></name><name><surname>Paquola</surname><given-names>AC</given-names></name><name><surname>Machado</surname><given-names>AA</given-names></name><name><surname>Festa</surname><given-names>F</given-names></name><name><surname>Yamamoto</surname><given-names>D</given-names></name><name><surname>Alvarenga</surname><given-names>R</given-names></name><name><surname>da Silva</surname><given-names>CC</given-names></name><name><surname>Brito</surname><given-names>GC</given-names></name><name><surname>Simon</surname><given-names>SD</given-names></name><name><surname>Moreira-Filho</surname><given-names>CA</given-names></name><name><surname>Leite</surname><given-names>KR</given-names></name><name><surname>Camara-Lopes</surname><given-names>LH</given-names></name><name><surname>Campos</surname><given-names>FS</given-names></name><name><surname>Gimba</surname><given-names>E</given-names></name><name><surname>Vignal</surname><given-names>GM</given-names></name><name><surname>El-Dorry</surname><given-names>H</given-names></name><name><surname>Sogayar</surname><given-names>MC</given-names></name><name><surname>Barcinski</surname><given-names>MA</given-names></name><name><surname>da Silva</surname><given-names>AM</given-names></name><name><surname>Verjovski-Almeida</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer</article-title><source>Oncogene</source><volume>23</volume><fpage>6684</fpage><lpage>6692</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207880</pub-id><pub-id pub-id-type="pmid">15221013</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salagierski</surname><given-names>M</given-names></name><name><surname>Verhaegh</surname><given-names>GW</given-names></name><name><surname>Jannink</surname><given-names>SA</given-names></name><name><surname>Smit</surname><given-names>FP</given-names></name><name><surname>Hessels</surname><given-names>D</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer</article-title><source>The Prostate</source><volume>70</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/pros.21040</pub-id><pub-id pub-id-type="pmid">19760627</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salameh</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>AK</given-names></name><name><surname>Cardó-Vila</surname><given-names>M</given-names></name><name><surname>Nunes</surname><given-names>DN</given-names></name><name><surname>Efstathiou</surname><given-names>E</given-names></name><name><surname>Staquicini</surname><given-names>FI</given-names></name><name><surname>Dobroff</surname><given-names>AS</given-names></name><name><surname>Marchiò</surname><given-names>S</given-names></name><name><surname>Navone</surname><given-names>NM</given-names></name><name><surname>Hosoya</surname><given-names>H</given-names></name><name><surname>Lauer</surname><given-names>RC</given-names></name><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Salmeron</surname><given-names>CC</given-names></name><name><surname>Hoang</surname><given-names>A</given-names></name><name><surname>Newsham</surname><given-names>I</given-names></name><name><surname>Lima</surname><given-names>LA</given-names></name><name><surname>Carraro</surname><given-names>DM</given-names></name><name><surname>Oliviero</surname><given-names>S</given-names></name><name><surname>Kolonin</surname><given-names>MG</given-names></name><name><surname>Sidman</surname><given-names>RL</given-names></name><name><surname>Do</surname><given-names>KA</given-names></name><name><surname>Troncoso</surname><given-names>P</given-names></name><name><surname>Logothetis</surname><given-names>CJ</given-names></name><name><surname>Brentani</surname><given-names>RR</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Dias-Neto</surname><given-names>E</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3</article-title><source>PNAS</source><volume>112</volume><fpage>8403</fpage><lpage>8408</lpage><pub-id pub-id-type="doi">10.1073/pnas.1507882112</pub-id><pub-id pub-id-type="pmid">26080435</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Fuchs</surname><given-names>HE</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CA cancer</article-title><source>Jornal Dos Clinicos</source><volume>71</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21654</pub-id><pub-id pub-id-type="pmid">33433946</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>SC</given-names></name><name><surname>Yeh</surname><given-names>CM</given-names></name><name><surname>Lin</surname><given-names>CW</given-names></name><name><surname>Hsieh</surname><given-names>YH</given-names></name><name><surname>Chuang</surname><given-names>CY</given-names></name><name><surname>Tang</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Yang</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A novel melatonin-regulated lncrna suppresses TPA-induced oral cancer cell motility through replenishing PRUNE2 expression</article-title><source>Journal of Pineal Research</source><volume>71</volume><elocation-id>e12760</elocation-id><pub-id pub-id-type="doi">10.1111/jpi.12760</pub-id><pub-id pub-id-type="pmid">34339541</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>AA</given-names></name><name><surname>Marchiò</surname><given-names>S</given-names></name><name><surname>Dias-Neto</surname><given-names>E</given-names></name><name><surname>Nunes</surname><given-names>DN</given-names></name><name><surname>da Silva</surname><given-names>IT</given-names></name><name><surname>Chackerian</surname><given-names>B</given-names></name><name><surname>Barry</surname><given-names>M</given-names></name><name><surname>Lauer</surname><given-names>RC</given-names></name><name><surname>Giordano</surname><given-names>RJ</given-names></name><name><surname>Sidman</surname><given-names>RL</given-names></name><name><surname>Wheeler</surname><given-names>CM</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Going viral? linking the etiology of human prostate cancer to the <italic>pca3</italic> long noncoding RNA and oncogenic viruses</article-title><source>EMBO Molecular Medicine</source><volume>9</volume><fpage>1327</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.15252/emmm.201708072</pub-id><pub-id pub-id-type="pmid">28751581</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="web"><person-group person-group-type="author"><collab>University of North Carolina TCGA Genome Characterization Center</collab></person-group><year iso-8601-date="2017">2017</year><article-title>TCGA prostate adenocarcinoma (PRAD) gene expression by rnaseq (polya+ illuminahiseq)</article-title><ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/datapages/?dataset=TCGA.PRAD.sampleMap%2FHiSeqV2&amp;host=https%3A%2F%2Ftcga.xenahubs.net&amp;removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443">https://xenabrowser.net/datapages/?dataset=TCGA.PRAD.sampleMap%2FHiSeqV2&amp;host=https%3A%2F%2Ftcga.xenahubs.net&amp;removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443</ext-link><date-in-citation iso-8601-date="2019-05-19">May 19, 2019</date-in-citation></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandesompele</surname><given-names>J</given-names></name><name><surname>De Preter</surname><given-names>K</given-names></name><name><surname>Pattyn</surname><given-names>F</given-names></name><name><surname>Poppe</surname><given-names>B</given-names></name><name><surname>Van Roy</surname><given-names>N</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name><name><surname>Speleman</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes</article-title><source>Genome Biology</source><volume>3</volume><elocation-id>RESEARCH0034</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2002-3-7-research0034</pub-id><pub-id pub-id-type="pmid">12184808</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leenders</surname><given-names>GJLH</given-names></name><name><surname>van der Kwast</surname><given-names>TH</given-names></name><name><surname>Grignon</surname><given-names>DJ</given-names></name><name><surname>Evans</surname><given-names>AJ</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>Kweldam</surname><given-names>CF</given-names></name><name><surname>Litjens</surname><given-names>G</given-names></name><name><surname>McKenney</surname><given-names>JK</given-names></name><name><surname>Melamed</surname><given-names>J</given-names></name><name><surname>Mottet</surname><given-names>N</given-names></name><name><surname>Paner</surname><given-names>GP</given-names></name><name><surname>Samaratunga</surname><given-names>H</given-names></name><name><surname>Schoots</surname><given-names>IG</given-names></name><name><surname>Simko</surname><given-names>JP</given-names></name><name><surname>Tsuzuki</surname><given-names>T</given-names></name><name><surname>Varma</surname><given-names>M</given-names></name><name><surname>Warren</surname><given-names>AY</given-names></name><name><surname>Wheeler</surname><given-names>TM</given-names></name><name><surname>Williamson</surname><given-names>SR</given-names></name><name><surname>Iczkowski</surname><given-names>KA</given-names></name><collab>ISUP Grading Workshop Panel Members</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma</article-title><source>The American Journal of Surgical Pathology</source><volume>44</volume><fpage>e87</fpage><lpage>e99</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000001497</pub-id><pub-id pub-id-type="pmid">32459716</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>McPherson</surname><given-names>JR</given-names></name><name><surname>Stevenson</surname><given-names>M</given-names></name><name><surname>van Eijk</surname><given-names>R</given-names></name><name><surname>Heng</surname><given-names>HL</given-names></name><name><surname>Newey</surname><given-names>P</given-names></name><name><surname>Gan</surname><given-names>A</given-names></name><name><surname>Ruano</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Poon</surname><given-names>SL</given-names></name><name><surname>Ong</surname><given-names>CK</given-names></name><name><surname>van Wezel</surname><given-names>T</given-names></name><name><surname>Cavaco</surname><given-names>B</given-names></name><name><surname>Rozen</surname><given-names>SG</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Teh</surname><given-names>BT</given-names></name><name><surname>Thakker</surname><given-names>RV</given-names></name><name><surname>Morreau</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>100</volume><fpage>E360</fpage><lpage>E364</lpage><pub-id pub-id-type="doi">10.1210/jc.2014-3238</pub-id><pub-id pub-id-type="pmid">25387265</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Results</title><p>In the discovery cohort, to further assess the association between time to biochemical recurrence and the gene expression of <italic>PRUNE2</italic> and <italic>PCA3</italic> and the ratio of their expressions, and to take into account possible confounding by clinicopathological variables, we performed multivariate Cox proportional hazards regression modeling (raw data available in Appendix tables and code). As there may be possible correlations between tumor Gleason Grade (GG) and tumor pathological stage (PS), we created a composite categorical variable (‘GG-PS’) representing the four possibilities in the discovery cohort: 3+4/pT2, 4+3/pT2, 3+4/pT3a, 4+3/pT3a. We then used two approaches to model outcome.</p><p>In the first approach, we fit four different Cox models. The explanatory variables in these models were as follows: model 1 (‘GG_PS model’) – GG_PS only; model 2 (‘<italic>PRUNE2</italic> model’) – <italic>PRUNE2</italic> expression, age, race, GG_PS, and interaction between GG_PS and <italic>PRUNE2</italic> expression; model 3 (‘PCA3 model’) – <italic>PCA3</italic> expression, age, race, GG_PS, and interaction between GG_PS and <italic>PCA3</italic> expression; and model 4 (‘Ratio model’) – <italic>PRUNE2/PCA3</italic> ratio, age, race, GG_PS, and interaction between GG_PS and the ratio. The goodness-of-fit of the models were compared using the Akaike information criterion (AIC), and the results are summarized in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. As a lower value of AIC indicates a better association fit, the model comparison indicates that the model with GG_PS only (model 1) represents the best fit for the data, and does not suggest that the expression of <italic>PRUNE2</italic>, <italic>PCA3,</italic> or their ratio adds to the ability of pathology grade and stage to predict biochemical recurrence.</p><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Discovery cohort multivariable model.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Model</th><th align="left" valign="bottom">Akaike information criterion score</th></tr></thead><tbody><tr><td align="left" valign="bottom">PS_GG model</td><td align="char" char="." valign="bottom">157.2</td></tr><tr><td align="left" valign="bottom"><italic>PRUNE2</italic> model</td><td align="char" char="." valign="bottom">162.9</td></tr><tr><td align="left" valign="bottom"><italic>PCA3</italic> model</td><td align="char" char="." valign="bottom">166.2</td></tr><tr><td align="left" valign="bottom">Ratio model</td><td align="char" char="." valign="bottom">162.2</td></tr></tbody></table></table-wrap><p>As a second multivariable approach to an assessment of the association of time to biochemical recurrence and gene expression, we created a multivariable model, including the following variables: expression of <italic>PRUNE2</italic>, expression of <italic>PCA3</italic>, age, race, the composite variable GG_PS, interaction between <italic>PRUNE2</italic> expression and GG_PS, and interaction between <italic>PCA3</italic> expression and GG_PS. In this case, a stepwise selection algorithm was used for model selection, and only the model with Gleason score and pathological stage (GG_PS) was selected, as none of the other variables had a p-value less than the specified significance level of 0.25 (data not shown).</p><p>In the TCGA cohort, we used Cox proportional hazards modeling to assess the association of tumor PCA3 expression, adjusting for tumor grade, tumor stage, and age at diagnosis. The results are summarized in <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>. Briefly, on multivariable modeling, there was an association between tumor grade and stage with recurrence, we did not find that tumor <italic>PCA3</italic> expression was associated with biochemical recurrence (HR, 0.96; 95% CI 0.87–1.04, [p-value = 0.36]).</p><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Validation cohort multivariable Cox model.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Hazard ratio (HR)</th><th align="left" valign="bottom">95% CI</th><th align="left" valign="bottom">p-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>PCA3</italic></td><td align="char" char="." valign="bottom">0.963</td><td align="char" char="ndash" valign="bottom">0.888–1.044</td><td align="char" char="." valign="bottom">0.36</td></tr><tr><td align="left" valign="bottom">Gleason Grade</td><td align="char" char="." valign="bottom">1.558</td><td align="char" char="ndash" valign="bottom">1.147–2.117</td><td align="char" char="." valign="bottom">&lt;0.01</td></tr><tr><td align="left" valign="bottom">Pathological stage T3</td><td align="char" char="." valign="bottom">3.596</td><td align="char" char="ndash" valign="bottom">1.360–9.512</td><td align="char" char="." valign="bottom">&lt;0.01</td></tr><tr><td align="left" valign="bottom">Pathological stage T4</td><td align="char" char="." valign="bottom">1.860</td><td align="char" char="ndash" valign="bottom">0.206–16.82</td><td align="char" char="." valign="bottom">0.58</td></tr><tr><td align="left" valign="bottom">Age at diagnosis</td><td align="char" char="." valign="bottom">1.000</td><td align="char" char="ndash" valign="bottom">0.960–1.043</td><td align="char" char="." valign="bottom">0.99</td></tr></tbody></table></table-wrap></sec><sec sec-type="appendix" id="s9"><title>Methods</title><sec sec-type="appendix" id="s9-1"><title>Statistical analysis for quantifying the expression of PCA3 and PRUNE2</title><p>There were combinations of assays and control genes used for quantifying the expression of <italic>PCA3</italic> and <italic>PRUNE2</italic> in this study. Explicitly, there were nine duplex mixes for <italic>PRUNE2</italic>: PR1C1, PR1C2, PR1C3, PR2C1, PR2C2, PR2C3, PR3C1, PR3C2, PR3C3; and six duplex mixes for <italic>PCA3</italic>: PC1C1, PC1C2, PC1C3, PC2C1, PC2C2, PC3C3, where the first three letters denote an assay and last two letters denote a control gene being used in a particular run. For example, PC2C2 denotes the second assay for <italic>PCA3</italic> (Hs03462121_m1, detailed in Methods) and the second endogenous control gene (Hs02800695_m1, detailed in Methods) were used for that specific experiment.</p><p><inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> is to denote the logarithmic number of PCR cycle when the fluorescent signal passes a threshold value. Let <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">u</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mtext> </mml:mtext><mml:mtext> </mml:mtext><mml:mrow><mml:mi mathvariant="normal">c</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> and we had <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> to quantify the gene expression (relative to a control gene), resulting in a positive value meaning an upregulated gene’s expression.</p><p>The experiment was completed three times for each gene duplex mix, for example, we have three data points of PC2C2 measure for a tumor sample. The median of the three <inline-formula><mml:math id="inf4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> values is summarized to estimate the gene expression of a particular gene duplex mix. We then looked at both mean and median of nine estimates for <italic>PRUNE2</italic> and six estimates for <italic>PCA3</italic>, separately (data not shown). We did not see any significant difference utilizing mean or median in this or subsequent analyses.</p></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81929.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v408z34</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.25.22281522" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.25.22281522"/></front-stub><body><p>In this manuscript, the upregulation of PCA3 and downregulation of PRUNE2 in prostate cancer as compared with normal prostate were first discovered. The conclusions are reached through two large-scale clinical-derived cohorts, supporting that PCA3 and PRUNE2 function as an oncogene and a tumor suppressor gene, respectively. The major findings opened up a novel avenue for prostate cancer treatment.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81929.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v408z34</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.25.22281522">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.10.25.22281522v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: From experimental discovery to validation in two independent patient cohorts&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Caigang Liu as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Knockdown and/or overexpression would be preferred to evaluate the role of PCA3 or PRUNE2 in prostate cancer cells.</p><p>2) Some issues are expected to be mentioned in the Discussion, including the reason that increase in PCA3 decrease in Figure 1A appears to be quite larger than the decrease in PRUNE2, and the possible utility of liquid biopsy for PCA3 beyond tissue analysis.</p><p>3) The finding that PCA3 may be related to low serum testosterone in these patients needs further data to support it.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The conclusions of this paper are mostly well supported by data, but some analyses need to be clarified and extended.</p><p>Suggestion:</p><p>Knockdown and/or overexpression should be applied to evaluate the role of PCA3 or PRUNE2 in prostate cancer cells.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>In the present manuscript, Lauer and colleagues analyzed the tumor and adjacent normal prostatic glandular tissue expression of the LncRNA PCA3 and PRUNE2 in two independent retrospective cohorts of patients. The authors observed PCA3 up-regulation and PRUNE2 down-regulation in prostate cancer compared with the adjacent normal prostate across all tumor grades and stages. The authors also found there was no association between tumor PCA3 or PRUNE2 expression and biochemical recurrence. The findings provided evidence for the functional reciprocal co-regulation of PCA3 and PRUNE2 in the setting of early tumorigenesis but not in late events in human prostate cancer. Overall, this study suggests the PCA3/PRUNE2 regulatory axis as an attractive early molecular target candidate to guide the choice of appropriate treatment for human prostate cancer. The strengths of this study are that the authors found consistent findings by analyzing two independent well-characterized clinically annotated primary prostate cancer cohorts. PCA3 expression assessed by using tissue, not urine is also novel. However, the authors propose that the low expression of PCA3 may be related to low serum testosterone in these patients. It would be better if the authors have further data to support it.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81929.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Knockdown and/or overexpression would be preferred to evaluate the role of PCA3 or PRUNE2 in prostate cancer cells.</p></disp-quote><p>Thank you for this insightful suggestion. Indeed, we have previously performed and reported these experiments (Salameh et al. <italic>Proc. Natl. Acad. Sci. USA</italic> 112(27)8403-8408, 2015): We assessed the functional role of the <italic>PCA3/PRUNE2</italic> regulatory axis by using lentiviral constructs in prostate epithelial cells in vitro. We found that <italic>PRUNE2</italic> ectopic expression or <italic>PCA3</italic> silencing decreased proliferation and transformation, while ectopic <italic>PCA3</italic> expression or <italic>PRUNE2</italic> silencing led to an increase in cell proliferation and transformation. Together with the findings in the current work, those in vitro findings support the working hypotheses that <italic>PCA3</italic> acts as an oncogene, and <italic>PRUNE2</italic> as a tumor suppressor in prostate cancer. We have now reinforced the data mentioned above in the revised manuscript (pp. 6-7, 18-19).</p><disp-quote content-type="editor-comment"><p>2) Some issues are expected to be mentioned in the Discussion, including the reason that increase in PCA3 decrease in Figure 1A appears to be quite larger than the decrease in PRUNE2, and the possible utility of liquid biopsy for PCA3 beyond tissue analysis.</p></disp-quote><p>We appreciate the useful suggestion towards the development liquid biopsy applications. We have now addressed this future tantalizing possibility in the Discussion of the revised manuscript (p. 20). We have also addressed the intriguing seemingly variable magnitudes of <italic>PCA3</italic> and <italic>PRUNE2</italic> in the Discussion of the revised manuscript (p. 18).</p><disp-quote content-type="editor-comment"><p>3) The finding that PCA3 may be related to low serum testosterone in these patients needs further data to support it.</p></disp-quote><p>We fully agree that further data will shed light on this question. As such, we have now clarified in the Discussion of the revised manuscript that the hypothesis originally put forward by Alshalalfa et al. (reference 19 of the revised manuscript) to explain the inverse association between <italic>PCA3</italic> levels and increasing grades and stages of prostatic cancer is an interesting open question to be addressed in further prospective clinical/epidemiological studies. In these retrospective cohorts, we do not have the data to directly assess that intriguing clinical hypothesis. However, one should also note that we have previously performed mechanistic experiments with testosterone analogues that yielded internally consistent results with our original hypothesis (Salameh et al. <italic>Proc. Natl. Acad. Sci. USA</italic> 112(27)8403-8408, 2015). Those aspects are now mentioned in the revised manuscript (p. 19 and reference 19).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The conclusions of this paper are mostly well supported by data, but some analyses need to be clarified and extended.</p><p>Suggestion:</p><p>Knockdown and/or overexpression should be applied to evaluate the role of PCA3 or PRUNE2 in prostate cancer cells.</p></disp-quote><p>We appreciate the careful review of the manuscript by Referee #1. As indicated above, we have previously performed these experiments (Salameh et al. <italic>Proc Natl Acad Sci USA</italic> 112(27)8403-8408, 2015); specifically, we experimentally assessed the functional role of the <italic>PCA3/PRUNE2</italic> regulatory axis by using lentiviral constructs in prostate epithelial cells in vitro to show that <italic>PRUNE2</italic> ectopic expression or <italic>PCA3</italic> silencing decreased proliferation and transformation, while ectopic <italic>PCA3</italic> expression or <italic>PRUNE2</italic> silencing led to an increase in cell proliferation and transformation. Those aspects are now discussed (pp. 6-7, 18-19 and reference 8) of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>In the present manuscript, Lauer and colleagues analyzed the tumor and adjacent normal prostatic glandular tissue expression of the LncRNA PCA3 and PRUNE2 in two independent retrospective cohorts of patients. The authors observed PCA3 up-regulation and PRUNE2 down-regulation in prostate cancer compared with the adjacent normal prostate across all tumor grades and stages. The authors also found there was no association between tumor PCA3 or PRUNE2 expression and biochemical recurrence. The findings provided evidence for the functional reciprocal co-regulation of PCA3 and PRUNE2 in the setting of early tumorigenesis but not in late events in human prostate cancer. Overall, this study suggests the PCA3/PRUNE2 regulatory axis as an attractive early molecular target candidate to guide the choice of appropriate treatment for human prostate cancer. The strengths of this study are that the authors found consistent findings by analyzing two independent well-characterized clinically annotated primary prostate cancer cohorts. PCA3 expression assessed by using tissue, not urine is also novel. However, the authors propose that the low expression of PCA3 may be related to low serum testosterone in these patients. It would be better if the authors have further data to support it.</p></disp-quote><p>We must agree with all these fine points. First, PCA3-based quantitative PCR is currently approved by the FDA and the EMA for clinical use, but only in urine assays. Thus, potential applications in patient-derived serum or tissue represent yet another novel aspect of the work reported here. Moreover, we have now expanded on the interesting hypothesis by Alshalalfa et al. (reference 19 of the revised manuscript) to explain the inverse association between PCA3 levels and increasing grades and stages of prostatic adenocarcinoma. Finally, while we do not have data to directly assess it in the cohorts in the retrospective cohorts presented here, one should note that we have previously performed mechanistic experiments with testosterone analogues that yielded internally consistent results with the original hypothesis (Salameh et al. <italic>Proc. Natl. Acad. Sci. USA</italic> 112(27)8403-8408, 2015). Those aspects are now mentioned in the revised manuscript (p. 19 and references 8 and 19).</p></body></sub-article></article>